AllSci News
BeOne appears to call time on EGFR degrader program
BeOne Medicines (formerly BeiGene; Basel, Switzerland; Nasdaq: ONC) has terminated its Phase I clinical trial of BG-60366, an orally administered chimeric...
University of Alabama at Birmingham backed with USD 2.34m NIAID grant for congenital syphilis trial
The University of Alabama at Birmingham has received a USD 2.34 million NIAID U01 cooperative agreement to conduct CONSISTENT, a Phase IV randomized...
Feinstein Institute receives USD 2.6m NIH grant for Alzheimer's disease eCIRP pathway research
The Feinstein Institute for Medical Research in Manhasset, New York, has received a USD 2.6 million NIH RF1 grant from the National Institute on Aging to...
UK MHRA approves Krystal Biotech’s Vyjuvek for dystrophic epidermolysis bullosa wounds
Krystal Biotech (Nasdaq: KRYS) has received UK MHRA marketing authorization for Vyjuvek (beremagene geperpavec-svdt) for the treatment of wounds in patients with…
Northwestern University receives USD 1.84m NIH grant for tauopathy gene therapy development
Northwestern University has received a USD 1.84 million NIH RF1 grant from the National Institute of Neurological Disorders and Stroke to advance...
Leads Biolabs pushing PD-L1/4-1BB BsAb opamtistomig into Phase III for extrapulmonary neuroendocrine carcinoma
Nanjing Leads Biolabs (HK: 9887.HK) has received approval from China's National Medical Products Administration to initiate a pivotal Phase III trial of...
China's SmartNuclide puts GPA33-directed pretargeted radioimmunotherapy into Phase I for CRC
A first-in-human trial of SNA028, a two-step pretargeted radioimmunotherapy targeting the GPA33 antigen, has been registered at Tianjin Medical University...
FDA accepts Viatris's NDA for MR-107A-02 fast-acting meloxicam for acute pain
Viatris (Nasdaq: VTRS) has submitted a New Drug Application (NDA) to the US FDA for MR-107A-02 (fast-acting meloxicam), an investigational oral...
CSPC's tissue factor-targeting ADC enters Phase I for advanced solid tumors
CSPC Pharmaceutical Group (HKEX: 1093) has initiated a first-in-human Phase I clinical trial of SYS6051, a tissue factor (TF)-targeting antibody-drug...
Cellio Therapeutics' iPSC-derived retinal pigment epithelium C.001 enters Phase I for RPE-mediated maculopathy
Cellio Therapeutics has opened a first-in-human Phase I trial of C.001, an autologous iPSC-derived retinal pigment epithelium cell therapy, in adults with...
Mestag's FAP-targeted lymphotoxin agonist aims to engineer tertiary lymphoid structures in cold tumors
Mestag Therapeutics, a Cambridge, UK-based clinical-stage biotech, has dosed the first patient in the STARLYS trial, a Phase I study evaluating MST-0312, a...
Relay Therapeutics' zovegalisib achieves 60% response rate in Phase II PIK3CA vascular anomalies trial
Relay Therapeutics (Nasdaq: RLAY) has reported initial zovegalisib clinical data from the Phase II ReInspire trial in PIK3CA-driven vascular anomalies,...
Japan approves Boehringer Ingelheim’s Jascayd for idiopathic and progressive pulmonary fibrosis
Boehringer Ingelheim’s Jascayd (nerandomilast) receives approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for the treatment of adults with idiopathic…
iECURE's ECUR-506 achieves 57% reduction in hyperammonemic events in OTC deficiency trial
iECURE reported statistically significant reductions in hyperammonemic events from the ECUR-506 OTC-HOPE trial, with the completed low-dose cohort showing a...
AeroRx posts positive Phase II data for nebulized LABA/LAMA drug in COPD
AeroRx Therapeutics has reported Phase 2a data for AERO-007, a nebulized fixed-dose combination of indacaterol and glycopyrrolate, showing statistically...
The AllSci Brief
Free, systematic R&D and deal news. Daily.